DNMT1 and hematologic disorder: The clinical and prognostic significance of these CT-antigen-specific T-cell responses on the clinical efficacy of DNMT inhibitor treatment in hematologic malignancies remains to be defined, although it suggests that combining DNMT inhibitors with vaccination to induce CT antigen expression in both tumors and CT antigen-specific T cells may prove beneficial (Figure 4B).